Sensei Biotherapeutics Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint
About The Event
Join us for the Sensei Biotherapeutics KOL Event, featuring Robert Schreiber, PhD (Washington University School of Medicine) who will provide background on VISTA (V-domain Immunoglobulin Suppressor of T cell Activation) and discuss the unmet medical needs present in the current immuno-oncology treatment landscape, and the importance of VISTA in developing highly selective therapeutics in cancer.
The Sensei Biotherapeutics leadership team will provide an overview of its conditionally active and fully human antibody, SNS-101, including a review of preclinical data. Using its TMAb™ platform, Sensei’s SNS-101 is being developed to selectively block the VISTA checkpoint within a low pH tumor microenvironment.
The event will conclude with a Fireside Chat with Dr. Schreiber, moderated by Neil Canavan (Managing Director, LifeSci Advisors), followed by a live Q&A session.